Harmonization of tumor mutation burden testing with comprehensive genomic profiling assays: an IQN Path initiative
Background Although conflicting results emerged from different studies, the tumor mutational burden (TMB) appears as one of most reliable biomarkers of sensitivity to immune checkpoint inhibitors. Several laboratories are reporting TMB values when performing comprehensive genomic profiling (CGP) wit...
Main Authors: | Nicola Normanno, Paolo Chiodini, Riziero Esposito Abate, Raffaella Pasquale, Alessandra Sacco, Vittorio Simeon, Monica Rosaria Maiello, Daniela Frezzetti |
---|---|
Format: | Article |
Language: | English |
Published: |
BMJ Publishing Group
2024-02-01
|
Series: | Journal for ImmunoTherapy of Cancer |
Online Access: | https://jitc.bmj.com/content/12/2/e007800.full |
Similar Items
-
Low Impact of Clonal Hematopoiesis on the Determination of RAS Mutations by Cell-Free DNA Testing in Routine Clinical Diagnostics
by: Cristin Roma, et al.
Published: (2022-08-01) -
Bioinformatics: From NGS Data to Biological Complexity in Variant Detection and Oncological Clinical Practice
by: Serena Dotolo, et al.
Published: (2022-08-01) -
Genomic alterations in cholangiocarcinoma: clinical significance and relevance to therapy
by: Marianeve Carotenuto, et al.
Published: (2022-04-01) -
Colorectal cancer genomic biomarkers in the clinical management of patients with metastatic colorectal carcinoma
by: Anna Maria Rachiglio, et al.
Published: (2020-02-01) -
Analisis Historis, Metode Dan Karakteristik Pendidikan Tasawuf Di Ma’had Aly IqnᾹ’ Ath-ThᾹlῙbin Pondok Pesantren Al-Anwar, Sarang, Rembang
by: Kholis Ali Mahmudi, et al.
Published: (2024-09-01)